Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Allogeneic Stem Cell Transplantation for Non-Malignant Diseases
NCT01019876Phase 3Completed
- Sponsor
- Columbia University
- Start
- Sep 2002
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of fludarabine, cyclophosphamide, busulfan, alemtuzumab, antithymocyte globulin rabbit in bone marrow failure syndrome (BMFS), immunodeficiency, Inborn errors of metabolism (IEM), histiocytosis, sponsored by Columbia University. Started Sep 2002; status: completed.
02
Drugs
fludarabinecyclophosphamidebusulfanalemtuzumabantithymocyte globulin rabbit
03
Conditions
bone marrow failure syndrome (BMFS)immunodeficiencyInborn errors of metabolism (IEM)histiocytosis
Beyond the preview
Go deeper on NCT01019876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019876.